Clinical Trial

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 7, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a single centre randomised controlled trial, comparing perioperative FLOT versus adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers. Patients with operable clinical T3 or above and N1 or above gastric and esophagastric junction cancer would be recruited. Participants would be randomised to perioperative FLOT versus adjuvant XELOX with curative radical gastrectomy. Primary outcome would be 3 year Disease Free Survival. It was calculated that 110 patients would be required to demonstrate the study hypothesis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-02-22; most recent amendment 2023-09-06.
Trial Details
NCT Number NCT05264896
Lead Sponsor Chinese University of Hong Kong
Conditions Cancer of Stomach, Adenocarcinoma
Enrollment 110 participants
Start Date 2022-03-21
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-07